BMRN

#890
BioMarin Pharmaceutical Inc. - Common Stock
54.1 1 USD
+2.73%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
53.50
55.24
Range Annuel
49.26
66.28
Changement quotidien
+2.73%
Changement Mensuel
-0.26%
Evolution sur 6 mois
-2.50%
Changement Annuel
-7.46%
Clôture Précédente
52.6 7
Open
53.5 0
Low
53.5 0
High
55.2 4
Volume
497
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 10.46 B
  • Employee 3 221
  • Founded N/A
  • CEO Alexander Hardy
  • Website www.biomarin.com
  • Headquarter Delaware, United States
  • FIGI BBG000CZWZ05
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
33.02
ratio cours/chiffre d'affaires
3.64

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.

Nouvelles